E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 3/28/2014 in the Prospect News PIPE Daily.

Antibe Therapeutics lifts private placement of stock to C$5 million

Non-brokered offering is selling common shares at C$0.60 per share

By Devika Patel

Knoxville, Tenn., March 28 - Antibe Therapeutics Inc. said it increased its non-brokered private placement of stock to C$5 million from C$3 million. The deal priced on March 21.

The company is selling common shares at C$0.60 apiece, which is an 18.92% discount to the March 20 closing share price of C$0.74.

Settlement is expected March 31.

Proceeds will be used for product development and general corporate purposes.

The pharmaceutical company is based in Toronto.

Issuer:Antibe Therapeutics Inc.
Issue:Common stock
Amount:C$5 million
Price:C$0.60
Warrants:No
Agent:Non-brokered
Pricing date:March 21
Upsized:March 28
Settlement date:March 31
Stock symbol:TSX Venture: ATE
Stock price:C$0.74 at close March 20
Market capitalization:C$25.12 million

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.